"Secretary of Health and Human Services Robert F. Kennedy, Jr., touted ibogaine as the most promising treatment for depression and PTSD, citing an unnamed department chair at Johns Hopkins as his source. However, experts argue that while ibogaine holds promise, the research does not fully support the overly optimistic claims made by advocates."
"Sandeep Nayak, medical director of the Johns Hopkins School of Medicine Center for Psychedelic and Consciousness Research, stated that the science for ibogaine is in a far more preliminary state than that of psilocybin, another psychedelic being researched for mental health treatment."
"Research on ibogaine is limited, particularly in the U.S. where it is classified as a Schedule I drug, making it illegal and hindering comprehensive studies. Concerns about ibogaine's safety include its potential to be toxic to the heart and the risk of sudden cardiac death."
The Trump administration is promoting ibogaine as a treatment for depression and PTSD, with Secretary Kennedy calling it the most promising option available. However, experts caution that the research on ibogaine is limited and preliminary compared to other psychedelics like psilocybin. Concerns about ibogaine's safety include its potential toxicity and risk of sudden cardiac death. The classification of ibogaine as a Schedule I drug in the U.S. further complicates research efforts, leading to a lack of comprehensive studies on its efficacy and safety.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]